valproic acid has been researched along with Fatigue in 7 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Fatigue: The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the present study, VPA in combination with two differentiating agents, 13-cis retinoic acid and 1,25-dihydroxyvitamin D3, was given to 19 previously untreated patients with MDS or CMML." | 6.73 | Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes. ( Hallman, H; Honkanen, T; Juvonen, E; Kauppila, M; Koistinen, P; Kutila, A; Mikkola, M; Nyländen, P; Poikonen, E; Rauhala, A; Savolainen, ER; Siitonen, T; Sinisalo, M; Suominen, M; Terävä, V; Timonen, T, 2007) |
| "Valproic acid has become a regular component of antiepileptic therapy." | 6.36 | [Valproic acid in the treatment of epilepsy with special emphasis on serum level determination (author's transl)]. ( Fröscher, W; Gugler, R; Schulz, HU, 1978) |
| "The side effects and possible side effects of the therapy with valproic acid were documented in 66 outpatients with epilepsy over a period of one year." | 3.66 | [Antiepileptic therapy with valproinic acid. Correlations of side effects and serum levels of valproinic acid]. ( Fröscher, W; Gugler, R; Schulz, HU, 1979) |
| " In the present study, VPA in combination with two differentiating agents, 13-cis retinoic acid and 1,25-dihydroxyvitamin D3, was given to 19 previously untreated patients with MDS or CMML." | 2.73 | Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes. ( Hallman, H; Honkanen, T; Juvonen, E; Kauppila, M; Koistinen, P; Kutila, A; Mikkola, M; Nyländen, P; Poikonen, E; Rauhala, A; Savolainen, ER; Siitonen, T; Sinisalo, M; Suominen, M; Terävä, V; Timonen, T, 2007) |
| "To determine an optimal biologic dose (OBD) of decitabine as a single agent and then the maximum-tolerated dose (MTD) of valproic acid (VA) combined with decitabine in acute myeloid leukemia (AML)." | 2.73 | Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. ( Blum, W; Byrd, JC; Chan, KK; Devine, H; Devine, SM; Grever, MR; Hackanson, B; Heerema, NA; Huynh, L; Kefauver, C; Klisovic, RB; Liu, S; Liu, Z; Lozanski, G; Marcucci, G; Murgo, A; Plass, C; Vukosavljevic, T, 2007) |
| "Valproic acid has become a regular component of antiepileptic therapy." | 2.36 | [Valproic acid in the treatment of epilepsy with special emphasis on serum level determination (author's transl)]. ( Fröscher, W; Gugler, R; Schulz, HU, 1978) |
| "Levetiracetam was independently associated with anger/aggression, nervousness/agitation, upset stomach, depression, and sleep disturbance; lamotrigine with nervousness/agitation, upset stomach, and difficulty concentrating; and valproic acid with upset stomach and shaky hands." | 1.43 | Specific adverse effects of antiepileptic drugs--A true-to-life monotherapy study. ( Fidzinski, P; Gaus, V; Holtkamp, M; Kowski, AB; Losch, F; Weissinger, F, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (28.57) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kowski, AB | 1 |
| Weissinger, F | 1 |
| Gaus, V | 1 |
| Fidzinski, P | 1 |
| Losch, F | 1 |
| Holtkamp, M | 1 |
| Coulter, DW | 1 |
| Walko, C | 1 |
| Patel, J | 1 |
| Moats-Staats, BM | 1 |
| McFadden, A | 1 |
| Smith, SV | 1 |
| Khan, WA | 1 |
| Bridges, AS | 1 |
| Deal, AM | 1 |
| Oesterheld, J | 1 |
| Davis, IJ | 1 |
| Blatt, J | 1 |
| Siitonen, T | 1 |
| Timonen, T | 1 |
| Juvonen, E | 1 |
| Terävä, V | 1 |
| Kutila, A | 1 |
| Honkanen, T | 1 |
| Mikkola, M | 1 |
| Hallman, H | 1 |
| Kauppila, M | 1 |
| Nyländen, P | 1 |
| Poikonen, E | 1 |
| Rauhala, A | 1 |
| Sinisalo, M | 1 |
| Suominen, M | 1 |
| Savolainen, ER | 1 |
| Koistinen, P | 1 |
| Blum, W | 1 |
| Klisovic, RB | 1 |
| Hackanson, B | 1 |
| Liu, Z | 1 |
| Liu, S | 1 |
| Devine, H | 1 |
| Vukosavljevic, T | 1 |
| Huynh, L | 1 |
| Lozanski, G | 1 |
| Kefauver, C | 1 |
| Plass, C | 1 |
| Devine, SM | 1 |
| Heerema, NA | 1 |
| Murgo, A | 1 |
| Chan, KK | 1 |
| Grever, MR | 1 |
| Byrd, JC | 1 |
| Marcucci, G | 1 |
| Van Wouwe, JP | 1 |
| Fröscher, W | 2 |
| Schulz, HU | 2 |
| Gugler, R | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Study of Decitabine in Combination With Valproic Acid in Patients With Selected Hematologic Malignancies[NCT00079378] | Phase 1 | 84 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| Randomized Phase II Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer.[NCT03467178] | Phase 2 | 119 participants (Anticipated) | Interventional | 2018-07-30 | Recruiting | ||
| In Vivo Study of Safety, Tolerability and Dosing Effect on SMN mRNA and Protein Levels of Valproic Acid in Patients With Spinal Muscular Atrophy[NCT00374075] | Phase 1 | 42 participants | Interventional | 2003-09-30 | Completed | ||
| Phase I/II Trial of Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy Type I (CARNI-VAL Type I)[NCT00661453] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Multi-center Phase II Trial of Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy (SMA CARNI-VAL Trial)[NCT00227266] | Phase 2 | 94 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00661453)
Timeframe: -2 weeks, time 0, 3 months, 6 months
| Intervention | g (Mean) | |||||
|---|---|---|---|---|---|---|
| Lean Mass Baseline | Lean Mass 3 months | Lean Mass 6 months | Fat Mass Baseline | Fat Mass 3 months | Fat Mass 6 months | |
| SMA Type 1 | 4317.15 | 4993.92 | 5133.83 | 3011.37 | 3618.25 | 4316.08 |
The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mV (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 2.28 | 2.32 |
| Cohort 1b Sitters Treatment | 2.93 | 2.37 |
| Cohort 2 Standers and Walkers - Treatment | 5.52 | 6.56 |
The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mV (Median) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 1.91 | 1.44 |
| Cohort 1b Sitters Treatment | 2.2 | 1.8 |
| Cohort 2 Standers and Walkers - Treatment | 5.3 | 5.85 |
The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mVms (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 5.46 | 5.28 |
| Cohort 1b Sitters Treatment | 5.45 | 5.26 |
| Cohort 2 Standers and Walkers - Treatment | 14.85 | 16.26 |
The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mVms (Median) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 3.6 | 3.74 |
| Cohort 1b Sitters Treatment | 4.6 | 3.4 |
| Cohort 2 Standers and Walkers - Treatment | 13.65 | 16.85 |
Comparison of Modified Hammersmith Change from baseline to 6 months. Scores range from 0 to 40. A higher score indicates a better outcome. This scale is used to assess gross motor abilities of non-ambulant children with SMA in multiple research trials as well as in clinical settings. (NCT00227266)
Timeframe: 0 months, 6 months
| Intervention | Score (Mean) | ||
|---|---|---|---|
| Baseline visit (0 weeks) | 6 Month visit (V2) | Change from Baseline | |
| Cohort 1a Sitters Placebo Then Treatment | 20.0 | 20.6 | 0.6 |
| Cohort 1b Sitters Treatment | 16.6 | 16.8 | 0.2 |
"Baseline Modified Hammersmith Extend testing. The baseline test is the score they receive during their screening visits. This scale ranges from 0 to 56. A higher score indicates a better outcome.~This scale is used to assess gross motor abilities of children with SMA in multiple research trials as well as in clinical settings." (NCT00227266)
Timeframe: 1 month prior to enrollment, at enrollment (0 months)
| Intervention | Score (Mean) | |
|---|---|---|
| Modified Hammersmith Extend at S1 (-4 weeks) | Modified Hammersmith Extend at S2 (0 weeks) | |
| Cohort 2 Experimental | 47.0 | 48.3 |
1 review available for valproic acid and Fatigue
| Article | Year |
|---|---|
[Valproic acid in the treatment of epilepsy with special emphasis on serum level determination (author's transl)].
Topics: Blood Platelets; Drug Interactions; Electroencephalography; Epilepsy; Fatigue; Half-Life; Humans; Ph | 1978 |
3 trials available for valproic acid and Fatigue
| Article | Year |
|---|---|
Valproic acid reduces the tolerability of temsirolimus in children and adolescents with solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Diphenhydramine | 2013 |
Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes.
Topics: Acetylation; Aged; Aged, 80 and over; Calcitriol; Cheilitis; Chemical and Drug Induced Liver Injury; | 2007 |
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Brain D | 2007 |
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Brain D | 2007 |
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Brain D | 2007 |
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Brain D | 2007 |
3 other studies available for valproic acid and Fatigue
| Article | Year |
|---|---|
Specific adverse effects of antiepileptic drugs--A true-to-life monotherapy study.
Topics: Adult; Aged; Anticonvulsants; Anxiety; Carbamazepine; Depression; Drug-Related Side Effects and Adve | 2016 |
Carnitine deficiency during valproic acid treatment.
Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma | 1995 |
Carnitine deficiency during valproic acid treatment.
Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma | 1995 |
Carnitine deficiency during valproic acid treatment.
Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma | 1995 |
Carnitine deficiency during valproic acid treatment.
Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma | 1995 |
Carnitine deficiency during valproic acid treatment.
Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma | 1995 |
Carnitine deficiency during valproic acid treatment.
Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma | 1995 |
Carnitine deficiency during valproic acid treatment.
Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma | 1995 |
Carnitine deficiency during valproic acid treatment.
Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma | 1995 |
Carnitine deficiency during valproic acid treatment.
Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma | 1995 |
[Antiepileptic therapy with valproinic acid. Correlations of side effects and serum levels of valproinic acid].
Topics: Acne Vulgaris; Anemia, Aplastic; Epilepsy; Fatigue; Gastrointestinal Diseases; Humans; Leukopenia; T | 1979 |